Excavation for adverse events signals of atezolizumab

DI Panpan; HU Yunfei; MENG Xiangsong; QIAN Hui; JIA Shuyun

doi:10.6039/j.issn.1001-0408.2022.24.16

您当前的位置：

首页 >

文章列表页 >

Excavation for adverse events signals of atezolizumab

更新时间：2023-02-22

- Excavation for adverse events signals of atezolizumab
- ZHONGGUO YAOFANG Vol. 33, Issue 24, Pages: 3025-3028(2022)
- 作者机构：
  
  1.亳州市人民医院静配中心，安徽亳州　236800
  2.亳州学院中药学院，安徽亳州　236800
  3.亳州市人民医院呼吸与危重症医学科，安徽亳州　236800
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.24.16
  CLC： R969.3;979.1
- Published：30 December 2022，
  
  Received：05 May 2022，
  
  Revised：13 October 2022，
扫描看全文
狄潘潘,胡云飞,孟祥松等.阿替利珠单抗的不良事件风险信号挖掘 ^Δ[J].中国药房,2022,33(24):3025-3028.

DI Panpan,HU Yunfei,MENG Xiangsong,et al.Excavation for adverse events signals of atezolizumab[J].ZHONGGUO YAOFANG,2022,33(24):3025-3028.
狄潘潘,胡云飞,孟祥松等.阿替利珠单抗的不良事件风险信号挖掘 ^Δ[J].中国药房,2022,33(24):3025-3028. DOI： 10.6039/j.issn.1001-0408.2022.24.16.

DI Panpan,HU Yunfei,MENG Xiangsong,et al.Excavation for adverse events signals of atezolizumab[J].ZHONGGUO YAOFANG,2022,33(24):3025-3028. DOI： 10.6039/j.issn.1001-0408.2022.24.16.

摘要

目的

挖掘阿替利珠单抗上市后的药品不良事件（ADEs）风险信号，为其临床合理使用提供参考。

方法

收集FAERS数据库中阿替利珠单抗从上市（2016年5月18日）至2022年3月31日的ADEs报告。采用报告比值比（ROR）法和综合标准法（以下简称“MHRA法”）对阿替利珠单抗的ADEs风险信号进行挖掘，利用《国际医学用语词典》（23.0版）药物不良反应术语集中的首选术语（PT）和系统器官（SOC）进行描述和分类。

结果

共收集到16 051份以阿替利珠单抗为首要怀疑药物的ADEs报告，挖掘出401个PT，涉及17个SOC。16 051份报告中，以男性患者居多（51.64%），年龄主要分布在19～64岁和≥65岁。按报告数排序，ADEs主要表现为发热、疾病进展、间质性肺病、贫血症和肺炎等，累及的SOC包括肾脏及泌尿系统疾病，良性、恶性及性质不明的肿瘤（包括囊肿和息肉）和内分泌系统疾病等；按信号强度排序，发现说明书未收录的ADEs包括黄斑增厚、副肿瘤神经综合征、反应性穿孔性胶原病、副肿瘤性皮肌炎、抗红细胞抗体阳性和肺结节病。

结论

临床在使用阿替利珠单抗时，除关注患者可能出现说明书中已收录的ADEs外，还应重点关注眼部、神经及皮肤系统方面的ADEs，以保障患者用药安全。

Abstract

OBJECTIVE

To excavate the risk signals of adverse drug events （ADEs） of atezolizumab after marketing， so as to provide a reference for rational use of atezolizumab.

METHODS

Using the FAERS database， the ADEs of atezolizumab were collected from marketing on May 18th 2016 to Mar. 31st 2022. The ADEs risk signals were mined by reported odds ratio （ROR） and medicines and Healthcare Products Regulatory Agency method （MHRA）， and then described and classified by preferred term （PT） and system organ classification （SOC） in the adverse drug reaction glossary of

Medical Dictionary for Regulatory Activities

（MedDRA）（23.0 edition）.

RESULTS

A total of 16 051 ADEs reports with atezolizumab as the primary suspected drug were collected， and 401 PT were mined， involving 17 SOC. In 16 051 ADEs reports， the majority of patients were male （51.64%）， with main age distribution of 19 to 64 years old and more than 65 years old. According to the number of reports， ADEs were mainly focusing on pyrexia， disease progression， interstitial lung disease， anaemia， pneumonia， etc. The involved SOC includes kidney and urinary system diseases， benign， malignant and unknown tumors （including cysts and polyps）， endocrine system diseases， etc. According to the signal intensity， the new ADEs not specified in the drug instructions were macular thickening，paraneoplastic neurological syndrome， reactive perforating collagenosis， paraneoplastic dermatomyositis， anti-erythrocyte antibody positive and liver sarcoidosis.

CONCLUSIONS

In addition to the ADEs mentioned in the drug instructions，when using atezolizumab in clinic，attention should also be closely paid to ADEs of eyes， nervous and skin system， so as to ensure the safety of drug use in patients.

关键词

阿替利珠单抗药品不良事件警戒信号数据挖掘

Keywords

adverse drug eventswarning signaldata mining

references

FURUYA N，NISHINO M，WAKUDA K，et al. Real-world efficacy of atezolizumab in non-small cell lung cancer：a multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody[J]. Thorac Cancer，2021，12（5）：613-618.

CHIRASUTHAT P，CHAYAVICHITSILP P. Atezolizumab-induced Stevens-Johnson syndrome in a patient with non-small cell lung carcinoma[J]. Case Rep Dermatol，2018，10（2）：198-202.

LEVINE J J，SOMER R A，HOSOYA H，et al. Atezolizumab-induced encephalitis in metastatic bladder cancer：a case report and review of the literature[J]. Clin Genitourin Cancer，2017，15（5）：e847-e849.

THAKOLWIBOON S，KARUKOTE A，WILMS H. De novo myasthenia gravis induced by atezolizumab in a patient with urothelial carcinoma[J]. Cureus，2019，11（6）：e5002.

罗林，张佳颖，陈力，等. 基于美国FAERS数据库的托珠单抗不良事件信号挖掘[J]. 中国药房，2021，32（15）：1874-1879.

BÖHM R，BULIN C，WAETZIG V，et al. Pharma-covigilance-based drug repurposing：the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections[J]. Br J Clin Pharmacol，2021，87（11）：4421-4431.

任经天，王胜锋，侯永芳，等. 常用药品不良反应信号检测方法比较研究[J]. 中国药物警戒，2011，8（6）：356-359.

陈友生，缪健，梁义敏，等. 常用药品不良反应信号检测方法研究进展[J]. 中国药物依赖性杂志，2014，23（2）：89-92.

KITAGATAYA T，SUDA G，NAGASHIMA K，et al. Prevalence，clinical course，and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan[J]. J Gastroenterol Hepatol，2020，35（10）：1782-1788.

李铃，娄安琦，余俊先. 基于美国FAERS的PD-1/PD-L1抑制剂导致肺炎的数据分析[J]. 中国医院药学杂志，2021，41（13）：1288-1292.

HAANEN J B A G，CARBONNEL F，ROBERT C，et al. Management of toxicities from immunotherapy：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up[J]. Ann Oncol，2018，29（Suppl 4）：iv264-iv266.

TRAILL A，STAWELL R，HALL A，et al. Macular thi- ckening in acute anterior uveitis[J]. Ophthalmology，2007，114（2）：402.

BRESSLER N M，BEAULIEU W T，GLASSMAN A R，et al. Persistent macular thickening following intravitreous aflibercept，bevacizumab，or ranibizumab for central-involved diabetic macular edema with vision impairment：a secondary analysis of a randomized clinical trial[J]. JAMA Ophthalmol，2018，136（3）：257-269.

ERICHSEN J H，HOLM L M，FORSLUND JACOBSEN M，et al. Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery：a randomized clinical trial[J]. JAMA Ophthalmol，2021，139（10）：1062-1070.

DALVIN L A，SHIELDS C L，ORLOFF M，et al. CHECKPOINT INHIBITOR IMMUNE THERAPY：systemic indications and ophthalmic side effects[J]. Retina，2018，38（6）：1063-1078.

DOW E R，YUNG M，TSUI E. Immune checkpoint inhibitor-associated uveitis：review of treatments and outcomes[J]. Ocular Immunol Inflamm，2021，29（1）：203-211.

GRAUS F，DALMAU J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors[J]. Nat Rev Clin Oncol，2019，16（9）：535-548.

吕心怡，王国平，汤其强，等. 经典与非经典副肿瘤神经综合征临床特点分析[J]. 中华医学杂志，2021，101（9）：615-619.

YSHII L M，HOHLFELD R，LIBLAU R S. Inflammatory CNS disease caused by immune checkpoint inhibitors： status and perspectives[J]. Nat Rev Neurol，2017，13（12）：755-763.

KARPOUZIS A，GIATROMANOLAKI A，SIVRIDIS E，et al. Acquired reactive perforating collagenosis：current status[J]. J Dermatol，2010，37（7）：585-592.

LIU X Y，WANG H Y，WAN Y S，et al. Acquired perfora-ting dermatosis induced by PD-1 inhibitor：a case report[J]. Am J Dermatopathol，2021，43（12）：942-944.

ORMEROD E，ATWAN A，INTZEDY L，et al. Dermoscopy features of acquired reactive perforating collagenosis：a case series[J]. Dermatol Pract Concept，2018，8（4）：303-305.

LUKÁCS J，SCHLIEMANN S，ELSNER P. Treatment of acquired reactive perforating dermatosis： a systematic review[J]. J Dtsch Dermatol Ges，2018，16（7）：825-842.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Signal detection and analysis of the adverse events of ustekinumab based on OpenFDA database

计算机技术在医疗机构药品安全性监测中的应用进展Δ

数据挖掘技术在药品不良反应监测领域中的应用

Data mining of adverse drug reaction signals for ado-trastuzumab emtansine and brentuximab vedotin based on FAERS database

Excavation and Evaluation of ADR Signals of SGLT 2 Inhibitors

Related Author

CHEN Huiqing

XU Ting

陈　超徐元杰郭代红刘皈阳

张夙俞佳吕良忠

LIU Wei

ZHAI Suodi

CHENG Yinchu

HE Na

Related Institution

Dept. of Pharmacy， the Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰